A prospective, controlled, randomized, double blind, comparative, parallel, 2-arms study to evaluate the efficacy and safety of Epalrestat (150 mg) compared to Pregabalin (600 mg) in patients suffering from painful diabetic peripheral neuropathy.
Phase of Trial: Phase III/IV
Latest Information Update: 01 Sep 2016
At a glance
- Drugs Epalrestat (Primary) ; Pregabalin
- Indications Diabetic neuropathies
- Focus Therapeutic Use
- 08 Jul 2013 New trial record